Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Antabuse

(Disulfiram)

ApprovedSmall molecule

Disulfiram is a medication used to support recovery from alcohol addiction by creating an unpleasant physical reaction if someone drinks alcohol while taking it. This reaction discourages drinking by causing symptoms like flushing, nausea, vomiting, and chest pain that occur within 10 minutes of alcohol consumption.[2] Antabuse is currently approved and in use across 28 indications[4].[1]

Antabuse is one of 558 small molecule programs targeting HIV infection. It is currently in Approved.

28

Indications

46

Total Trials

6

Active Trials

557

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionActive, not recruiting

Methamphetamine DependenceActive, not recruiting

Alcohol-Related DisordersApproved

Cocaine AbuseActive, not recruiting

OsteosarcomaActive, not recruiting

Germ Cell TumorApproved

HIV-1 InfectionActive, not recruiting

Metastatic MelanomaActive, not recruiting

Cocaine DependenceActive, not recruiting

Alcohol AbuseActive, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Methamphetamine DependencePhase 1

Active, not recruiting

Alcohol-Related DisordersApproved

Approved

Cocaine AbusePhase 2

Active, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

Germ Cell TumorApproved

Approved

HIV-1 InfectionPreclinical

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Cocaine DependencePhase 2

Active, not recruiting

Alcohol AbusePhase 2

Active, not recruiting

Showing 10 of 27 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Antabuse

Tykerb

Voltaren

Blenoxane

Bristol-Myers Squibb

Spravato

Zinecard

CChildren's Oncology Group

Tricor

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Avastin

Zoladex

Luye Pharma Group Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Liposomal Doxorubicin

NCT05210374

Q1 2028

Phase 2Recruiting

Osteosarcoma

NCT07477457

Q2 2029

Phase 1Recruiting

Retinal Degeneration

NCT06319872

Q3 2029

Phase 1Recruiting

Anxiety

NCT06793488

Clinical

Trials by Indication[1]

Glioblastoma5 trials

Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform

Not yet recruiting·OOlympion Medical Center·Phase 2·NCT01777919·32 enrolled

Disulfiram in Recurrent Glioblastoma

Completed·SSahlgrenska University Hospital·Phase 2/3·NCT02678975·88 enrolled

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed·UUniversity of Ulm·Phase 1/2·NCT02770378·10 enrolled

Show 2 more trials

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed·WWashington University School of Medicine·Phase 1/2·NCT02715609·35 enrolled

Bioavailability of Disulfiram and Metformin in Glioblastomas

Terminated·SSahlgrenska University Hospital·Phase 1·NCT03151772·3 enrolled

Cocaine Abuse3 trials

Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Completed·YYale University·Phase 2·NCT00913484·177 enrolled

Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers

Completed·YYale University·N/A·NCT00580827·126 enrolled

Disulfiram for Cocaine Abuse

Completed·UUniversity of Arkansas·Phase 2·NCT00395850·118 enrolled

Glioblastoma Multiforme2 trials

Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide

Completed·WWashington University School of Medicine·Phase 1·NCT01907165·21 enrolled

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Terminated·WWake Forest University Health Sciences·Phase 2·NCT03363659·15 enrolled

COVID-192 trials

Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19

Completed·EETICA·Phase 2·NCT04594343·140 enrolled

DISulfiram for COvid-19 (DISCO) Trial

Terminated·UUniversity of California, San Francisco·Phase 2·NCT04485130·11 enrolled

Prostate Cancer2 trials

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·N/A·NCT01118741·19 enrolled

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Terminated·—·Phase 1·NCT02963051·9 enrolled

28 more indications

AIN2 trials

A Study of the Relationship Between Disulfiram and Cocaine Self-administration.

Completed·—·Phase 1/2·NCT00729300·52 enrolled

A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts

Withdrawn·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT02134002

Interaction2 trials

Disulfiram Interactions With HIV Medications: Clinical Implications

Completed·UUniversity of California, San Francisco·Phase 1·NCT00878306·40 enrolled

Interactions Between Cocaine and Ethanol and Disulfiram - 1

Unknown status·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT00094289·16 enrolled

Metastatic Melanoma2 trials

Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy

Terminated·UUniversity of California, Irvine·Phase 1·NCT00571116·9 enrolled

Disulfiram in Patients With Metastatic Melanoma

Completed·JJohn P. Fruehauf·Phase 1/2·NCT00256230·7 enrolled

Retinal Degeneration2 trials

Disulfiram for Treatment of Retinal Degeneration

Recruiting·UUniversity of Washington·Phase 1/2·NCT05626920·30 enrolled

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Recruiting·UUniversity of Rochester·Phase 1·NCT06319872·15 enrolled

Alcohol1 trial

Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

Completed·UUniversity of Pennsylvania·Phase 2·NCT00142844·208 enrolled

Osteosarcoma1 trial

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07477457·45 enrolled

Cocaine Dependence1 trial

Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone

Completed·UUniversity of Arkansas·Phase 2·NCT00218608·158 enrolled

Alcohol Dependence1 trial

Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence

Completed·FFinnish Institute for Health and Welfare·Phase 4·NCT00435435·243 enrolled

Liposomal Doxorubicin1 trial

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Recruiting·—·Phase 1·NCT05210374·24 enrolled

Lyme disease1 trial

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Completed·RResearch Foundation for Mental Hygiene, Inc.·Phase 1/2·NCT03891667·11 enrolled

Tics1 trial

Pharmacogenetics of Disulfiram for Cocaine

Completed·—·Phase 2·NCT00149630·93 enrolled

Refractory1 trial

Disulfiram and Cisplatin in Refractory TGCTs.

Completed·NNational Cancer Institute, Slovakia·Phase 2·NCT03950830·12 enrolled

Alcohol Use Disorder1 trial

Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder

Completed·VVirginia Commonwealth University·Phase 1/2·NCT04502589·4 enrolled

Pancreatic Cancer1 trial

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Terminated·MMayo Clinic·Phase 1·NCT02671890·16 enrolled

Breast Cancer1 trial

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Withdrawn·NNational Cancer Institute, Slovakia·Phase 2·NCT04265274

Amyloid1 trial

Disulfiram as a Modulator of Amyloid Precursor Protein-processing

Completed·JJohannes Gutenberg University Mainz··NCT03212599·17 enrolled

Age1 trial

CBT With Disulfiram and Contingency Management

Completed·YYale University·Phase 1·NCT00350870·181 enrolled

ALS1 trial

Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals

Completed·UUniversity of California, San Francisco·N/A·NCT01286259·16 enrolled

Alcohol Abuse1 trial

Disulfiram for Cocaine-Alcohol Abuse - 3

Completed·YYale University·Phase 2·NCT00000278

Refractory Solid Tumors1 trial

Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver

Completed·UUniversity of Utah·Phase 1·NCT00742911·21 enrolled

Methamphetamine Dependence1 trial

Open-Label Disulfiram for Methamphetamine Dependence

Completed·UUniversity of Arkansas·Phase 1/2·NCT00731133·15 enrolled

HIV infection1 trial

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT01944371·30 enrolled

Multiple Myeloma1 trial

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Terminated·UUniversity of Utah·Phase 1·NCT04521335·2 enrolled

AIDS1 trial

Depot Disulfiram for AIDS and ARC

Completed·SSt. Vincent's Medical Center·N/A·NCT00002065

Body Weight1 trial

Body Weight Response With Disulfiram in Humans

Unknown status·UUniversidad de Guanajuato·Phase 1·NCT05162001·10 enrolled

Anxiety1 trial

Anxiety During Abstinence in AUD

Recruiting·—·Phase 1·NCT06793488·60 enrolled

Breast Neoplasm Female1 trial

Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer

Completed·TThe Institute of Molecular and Translational Medicine, Czech Republic·Phase 2·NCT03323346·9 enrolled

Unspecified1 trial

Neural Mechanisms of Disulfiram Effects

Completed·NNew York State Psychiatric Institute·Phase 4·NCT02735577·7 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ANTABUSE

NDA NDA007883

Sources

References

[1]
ClinicalTrials.gov — 46 trial records for Disulfiram. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Antabuse drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Disulfiram compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Disulfiram. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA007883). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Aldehyde Dehydrogenase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Teva

Related News